ARTIS Ventures

Delix Therapeutics will initiate Phase Ib and Phase II studies in major depression in 2024 and 2025, respectively. #techbio #Biotech #psychedelics

Nature Portfolio shines a light on the good work being done by Unnatural Products Inc.

Last week, we had the pleasure of hosting our inaugural NeuroTech dinner for pioneering entrepreneurs and scientists who are building innovative technologies at the forefront of neuroscience. The event was a melting pot of perspectives, where key opinion leaders discussed topics including: 🔬🛠 How academic and industrial labs can work together to best drive innovation  🧠🗺 Advancements that could come from detailed structural mapping of the brain   🤖🦾 The role advancements in machine learning will play in future neuroprosthetic devices It was a delightful evening of electric discussions and camaraderie that left us more excited than ever about what the future holds! A special thanks to all who attended, including Doris Tsao, Max H., Anish Mitra, Milan Cvitkovic, Sumner L Norman, Vikash Gilja, Mei Z., David Moses, Amy Rochford, Erin Kunz, Guy Wilson, Raman Vilkhu, Austin Walne, Vasudev Bailey, and Stuart Peterson.

Congrats to Eko Health and the team! Honored to be a part of this journey as you work to change the face of heart disease and save countless lives.

Millions of people worldwide are affected by cancer. To meet the demand for cancer-treating therapies, Siren Biotechnology is developing a universal AAV immuno-gene therapy platform designed to reduce development and manufacturing timelines, while also working for numerous types of cancer. As part of the award, Siren Biotechnology will receive a wide range of support from MilliporeSigma, including Millipore® bioprocessing products, technologies and consultative services, and close partnership with the company to screen different media formulations to help optimize AAV yield. #techbio #oncology #lifesciences #biotech #genetherapy

Thanks to Biocom California for hosting a solid event yesterday, including a panel with Vasudev Bailey where he spoke on Exploring Funding Strategies in AI alongside Nan Li, Sarah Benson-Konforty, MD, Jorge Conde and Erin Cahill as moderator. #techbio #ai #healthcareai

Biocom California’s Converge Summit will bring together the brightest minds in these sectors to exchange ideas, break down barriers, strengthen relationships, and spark innovation. AV Managing Partner Vasudev Bailey is part of a strong speaker lineup that includes executives from all across bio. Attendees will have the chance to engage in critical conversations with industry leaders, explore the latest research and development, and gain valuable insights into the emerging trends and opportunities that are driving growth and innovation in the tech and healthcare sectors. #techbio #biotech #innovation #venturecapital #convergesummit

Their latest funding and support by Khosla Ventures further establishes Rad AI's credibility in the generative AI space and expands the team's ability to become the indisputable leader across the healthcare AI market. We’re excited to welcome Vinod Khosla and Khosla Ventures to support Rad AI’s next stage of growth.  Congratulations again to Doktor Gurson, Dr. Jeff Chang, and the Rad AI team on the exciting road ahead!  #generativeai #healthcare #radiology #techbio

Over the past decade, ARTIS has continued to focus its energies and resources on the growing opportunity to deliver frontier technologies, specifically AI, to the worlds of healthcare and biology. As investors who care deeply about both value creation and societal impact, it’s gratifying when founders we supported early in their development achieve significant milestones toward positively impacting patient outcomes. That’s especially true with today’s news of Rad AI’s $50M Series B, led by Khosla Ventures. Congrats to Doktor Gurson, Jeff Chang, and the entire team!

Congrats to Mat Legut, Neville Sanjana, and the team at OverT Bio, who are combining cutting-edge cell engineering technologies with big data approaches to address major unmet medical needs in solid tumors. “Everything OverT does is based on a patient-centric mission and focused on developing therapies that extend and enhance the lives of cancer patients,” said Dr. Vasudev Bailey, partner at ARTIS Ventures. #techbio #biotech #celltherapy